Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5.

PMID:
31142845
2.

TNF, but not hyperinsulinemia or hyperglycemia, is a key driver of obesity-induced monocytosis revealing that inflammatory monocytes correlate with insulin in obese male mice.

Breznik JA, Naidoo A, Foley KP, Schulz C, Lau TC, Loukov D, Sloboda DM, Bowdish DME, Schertzer JD.

Physiol Rep. 2018 Dec;6(23):e13937. doi: 10.14814/phy2.13937.

3.

Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice.

Cavallari JF, Anhê FF, Foley KP, Denou E, Chan RW, Bowdish DME, Schertzer JD.

Physiol Rep. 2018 Nov;6(22):e13930. doi: 10.14814/phy2.13930.

4.

Long term but not short term exposure to obesity related microbiota promotes host insulin resistance.

Foley KP, Zlitni S, Denou E, Duggan BM, Chan RW, Stearns JC, Schertzer JD.

Nat Commun. 2018 Nov 8;9(1):4681. doi: 10.1038/s41467-018-07146-5.

5.

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2018 Dec;564(7736):439-443. doi: 10.1038/s41586-018-0705-y. Epub 2018 Nov 7. Erratum in: Nature. 2019 Jun;570(7761):E53.

PMID:
30405246
6.

Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction.

Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, Loukov D, Schenck LP, Jury J, Foley KP, Schertzer JD, Larché MJ, Davidson DJ, Verdú EF, Surette MG, Bowdish DME.

Cell Host Microbe. 2018 Apr 11;23(4):570. doi: 10.1016/j.chom.2018.03.006. No abstract available.

7.

S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome.

Wang L, Rosé CD, Foley KP, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Fernández-Martín J, Guly C, Hachulla E, Harjacek M, Mackensen F, Merino R, Modesto C, Naranjo Hernández A, Pajot C, Ramanan AV, Thatayatikom A, Thomée C, Vastert S, Votta BJ, Bertin J, Wouters CH.

Rheumatology (Oxford). 2018 Apr 7. doi: 10.1093/rheumatology/key090. [Epub ahead of print]

8.

The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice.

McBride MJ, Foley KP, D'Souza DM, Li YE, Lau TC, Hawke TJ, Schertzer JD.

Am J Physiol Endocrinol Metab. 2017 Aug 1;313(2):E222-E232. doi: 10.1152/ajpendo.00060.2017. Epub 2017 May 23.

9.

Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.

Duggan BM, Foley KP, Henriksbo BD, Cavallari JF, Tamrakar AK, Schertzer JD.

Sci Rep. 2017 May 8;7(1):1578. doi: 10.1038/s41598-017-01822-0.

10.

Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4.

Cavallari JF, Fullerton MD, Duggan BM, Foley KP, Denou E, Smith BK, Desjardins EM, Henriksbo BD, Kim KJ, Tuinema BR, Stearns JC, Prescott D, Rosenstiel P, Coombes BK, Steinberg GR, Schertzer JD.

Cell Metab. 2017 May 2;25(5):1063-1074.e3. doi: 10.1016/j.cmet.2017.03.021. Epub 2017 Apr 20.

11.

Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction.

Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, Loukov D, Schenck LP, Jury J, Foley KP, Schertzer JD, Larché MJ, Davidson DJ, Verdú EF, Surette MG, Bowdish DME.

Cell Host Microbe. 2017 Apr 12;21(4):455-466.e4. doi: 10.1016/j.chom.2017.03.002. Erratum in: Cell Host Microbe. 2018 Apr 11;23 (4):570.

12.

MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2016 Sep 27;17(1):221-232. doi: 10.1016/j.celrep.2016.08.080.

13.

Impact of a Psychological Opioid-Risk Evaluation on Opioid Prescribing in Primary Care.

Vargovich AM, McNeil DW, Foley KP, Sperry J.

Fam Med. 2016 Jul;48(7):538-45.

14.

Different Th17 immunity in gut, liver, and adipose tissues during obesity: the role of diet, genetics, and microbes.

Cavallari JF, Denou E, Foley KP, Khan WI, Schertzer JD.

Gut Microbes. 2016;7(1):82-9. doi: 10.1080/19490976.2015.1127481.

15.

Curriculum development: Preparing trainees to care for children and adolescents with psychiatric disorders.

Foley KP, Haggerty TS, Harrison N.

Int J Psychiatry Med. 2015;50(1):50-9. doi: 10.1177/0091217415592360. Epub 2015 Jun 25.

PMID:
26113643
16.

MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.

Yu JW, Hoffman S, Beal AM, Dykon A, Ringenberg MA, Hughes AC, Dare L, Anderson AD, Finger J, Kasparcova V, Rickard D, Berger SB, Ramanjulu J, Emery JG, Gough PJ, Bertin J, Foley KP.

PLoS One. 2015 May 12;10(5):e0127083. doi: 10.1371/journal.pone.0127083. eCollection 2015.

17.

Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance.

Denou E, Lolmède K, Garidou L, Pomie C, Chabo C, Lau TC, Fullerton MD, Nigro G, Zakaroff-Girard A, Luche E, Garret C, Serino M, Amar J, Courtney M, Cavallari JF, Henriksbo BD, Barra NG, Foley KP, McPhee JB, Duggan BM, O'Neill HM, Lee AJ, Sansonetti P, Ashkar AA, Khan WI, Surette MG, Bouloumié A, Steinberg GR, Burcelin R, Schertzer JD.

EMBO Mol Med. 2015 Mar;7(3):259-74. doi: 10.15252/emmm.201404169.

18.

Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.

Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Cimaz R, Espada G, Fernandez-Martin J, Hachulla E, Harjacek M, Khubchandani R, Mackensen F, Merino R, Naranjo A, Oliveira-Knupp S, Pajot C, Russo R, Thomée C, Vastert S, Wulffraat N, Arostegui JI, Foley KP, Bertin J, Wouters CH.

Rheumatology (Oxford). 2015 Jun;54(6):1008-16. doi: 10.1093/rheumatology/keu437. Epub 2014 Nov 20.

19.

Blau syndrome, the prototypic auto-inflammatory granulomatous disease.

Wouters CH, Maes A, Foley KP, Bertin J, Rose CD.

Pediatr Rheumatol Online J. 2014 Aug 6;12:33. doi: 10.1186/1546-0096-12-33. eCollection 2014. Review.

20.

Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance.

Henriksbo BD, Lau TC, Cavallari JF, Denou E, Chi W, Lally JS, Crane JD, Duggan BM, Foley KP, Fullerton MD, Tarnopolsky MA, Steinberg GR, Schertzer JD.

Diabetes. 2014 Nov;63(11):3742-7. doi: 10.2337/db13-1398. Epub 2014 Jun 10.

21.

Ca²⁺ signals promote GLUT4 exocytosis and reduce its endocytosis in muscle cells.

Li Q, Zhu X, Ishikura S, Zhang D, Gao J, Sun Y, Contreras-Ferrat A, Foley KP, Lavandero S, Yao Z, Bilan PJ, Klip A, Niu W.

Am J Physiol Endocrinol Metab. 2014 Jul 15;307(2):E209-24. doi: 10.1152/ajpendo.00045.2014. Epub 2014 Jun 3.

22.

Bacterial peptidoglycan stimulates adipocyte lipolysis via NOD1.

Chi W, Dao D, Lau TC, Henriksbo BD, Cavallari JF, Foley KP, Schertzer JD.

PLoS One. 2014 May 14;9(5):e97675. doi: 10.1371/journal.pone.0097675. eCollection 2014.

23.
24.

Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation.

Klip A, Sun Y, Chiu TT, Foley KP.

Am J Physiol Cell Physiol. 2014 May 15;306(10):C879-86. doi: 10.1152/ajpcell.00069.2014. Epub 2014 Mar 5. Review.

25.

Myosin Va mediates Rab8A-regulated GLUT4 vesicle exocytosis in insulin-stimulated muscle cells.

Sun Y, Chiu TT, Foley KP, Bilan PJ, Klip A.

Mol Biol Cell. 2014 Apr;25(7):1159-70. doi: 10.1091/mbc.E13-08-0493. Epub 2014 Jan 29.

26.

Physician wellness in rural America: a review.

Haggerty TS, Fields SA, Selby-Nelson EM, Foley KP, Shrader CD.

Int J Psychiatry Med. 2013;46(3):303-13. Review.

PMID:
24741836
27.

Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles.

Boguslavsky S, Chiu T, Foley KP, Osorio-Fuentealba C, Antonescu CN, Bayer KU, Bilan PJ, Klip A.

Mol Biol Cell. 2012 Oct;23(20):4065-78. doi: 10.1091/mbc.E12-04-0263. Epub 2012 Aug 23.

28.

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.

Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26.

PMID:
22837008
29.

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.

Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17.

30.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y.

Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10.

31.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

32.

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J.

PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3.

33.

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK.

PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.

34.

NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance.

Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ, Klip A.

Endocrinology. 2010 Dec;151(12):5624-37. doi: 10.1210/en.2010-0437. Epub 2010 Oct 6.

PMID:
20926588
35.

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.

Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.

Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.

36.

Contraction-related stimuli regulate GLUT4 traffic in C2C12-GLUT4myc skeletal muscle cells.

Niu W, Bilan PJ, Ishikura S, Schertzer JD, Contreras-Ferrat A, Fu Z, Liu J, Boguslavsky S, Foley KP, Liu Z, Li J, Chu G, Panakkezhum T, Lopaschuk GD, Lavandero S, Yao Z, Klip A.

Am J Physiol Endocrinol Metab. 2010 May;298(5):E1058-71. doi: 10.1152/ajpendo.00773.2009. Epub 2010 Feb 16.

37.

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA.

Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660.

38.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.

Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26.

39.

Muscle metabolic, SR Ca(2+) -cycling responses to prolonged cycling, with and without glucose supplementation.

Duhamel TA, Green HJ, Stewart RD, Foley KP, Smith IC, Ouyang J.

J Appl Physiol (1985). 2007 Dec;103(6):1986-98. Epub 2007 Oct 4.

40.

Protection of muscle membrane excitability during prolonged cycle exercise with glucose supplementation.

Stewart RD, Duhamel TA, Foley KP, Ouyang J, Smith IC, Green HJ.

J Appl Physiol (1985). 2007 Jul;103(1):331-9. Epub 2007 Apr 5.

41.

Glucose supplements increase human muscle in vitro Na+-K+-ATPase activity during prolonged exercise.

Green HJ, Duhamel TA, Foley KP, Ouyang J, Smith IC, Stewart RD.

Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R354-62. Epub 2007 Apr 4.

42.

Routine and ritual elements in family mealtimes: contexts for child well-being and family identity.

Fiese BH, Foley KP, Spagnola M.

New Dir Child Adolesc Dev. 2006 Spring;(111):67-89. No abstract available.

PMID:
16646500
43.

The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice.

Gu W, Geddes BJ, Zhang C, Foley KP, Stricker-Krongrad A.

J Mol Neurosci. 2004;22(1-2):93-103.

PMID:
14742914
44.

MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity.

McArthur GA, Foley KP, Fero ML, Walkley CR, Deans AJ, Roberts JM, Eisenman RN.

Mol Cell Biol. 2002 May;22(9):3014-23.

45.

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.

Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH.

Immunity. 2001 Aug;15(2):289-302.

46.

The Mad protein family links transcriptional repression to cell differentiation.

McArthur GA, Laherty CD, Quéva C, Hurlin PJ, Loo L, James L, Grandori C, Gallant P, Shiio Y, Hokanson WC, Bush AC, Cheng PF, Lawrence QA, Pulverer B, Koskinen PJ, Foley KP, Ayer DE, Eisenman RN.

Cold Spring Harb Symp Quant Biol. 1998;63:423-33. Review. No abstract available.

PMID:
10384307
47.

Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network.

Foley KP, Eisenman RN.

Biochim Biophys Acta. 1999 May 31;1423(3):M37-47. Review.

PMID:
10382539
48.

Sequential expression of the MAD family of transcriptional repressors during differentiation and development.

Quéva C, Hurlin PJ, Foley KP, Eisenman RN.

Oncogene. 1998 Feb 26;16(8):967-77.

49.

Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation.

Foley KP, McArthur GA, Quéva C, Hurlin PJ, Soriano P, Eisenman RN.

EMBO J. 1998 Feb 2;17(3):774-85.

50.

Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.

Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM.

Oncogene. 1995 Dec 21;11(12):2487-501.

PMID:
8545105

Supplemental Content

Loading ...
Support Center